Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
about
Adjuvant Chemotherapy for the Completely Resected Stage IB Nonsmall Cell Lung Cancer: A Systematic Review and Meta-Analysis.Chemotherapy plus Erlotinib versus Chemotherapy Alone for Treating Advanced Non-Small Cell Lung Cancer: A Meta-Analysis.Clinical features and prognosis-associated factors of non-small cell lung cancer exhibiting symptoms of bone metastasis at the time of diagnosis.Efficacy of epidermal growth factor receptor inhibitors in combination with chemotherapy in advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials.Interleukin 12 shows a better curative effect on lung cancer than paclitaxel and cisplatin doublet chemotherapy.The role of docetaxel in the treatment of non-small cell lung cancer lung cancer: an update.SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015.Usefulness of dynamic contrast-enhanced magnetic resonance imaging for predicting treatment response to vinorelbine-cisplatin with or without recombinant human endostatin in bone metastasis of non-small cell lung cancer.Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials.Maintenance therapy in non-small cell lung cancer.Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles.Synchronous double primary cancer of the lung and nasal vestibule: A case report and literature review.Single-agent maintenance therapy for advanced non-small cell lung cancer (NSCLC): a systematic review and Bayesian network meta-analysis of 26 randomized controlled trials.Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations.First-Line Treatment with Carboplatin plus nab-Paclitaxel and Maintenance Monotherapy with nab-Paclitaxel for a Thymic Carcinoma: A Case Report.The role of weekly nanoparticle albumin bound paclitaxel monotherapy as second line or later treatment for advanced NSCLC in China.Palliative treatment efficacy of glucose inhibition combined with chemotherapy for non-small cell lung cancer with widespread bone and brain metastases: A case report.Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?Nuclear grade based on transbronchial cytology is an independent prognostic factor in patients with advanced, unresectable non-small cell lung cancer.Fibronectin protects lung cancer cells against docetaxel-induced apoptosis by promoting Src and caspase-8 phosphorylation.Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors.[Impact of the Pretreatment or Posttreatment NLR and PLR on the Response of First Line Chemotherapy and the Outcomes in Patients with Advanced Non-small Cell Lung Cancer].Telomerase-Mediated Strategy for Overcoming Non-Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance.
P2860
Q34479081-A830BF1A-54B8-4474-AB85-CD2B15A7DD9FQ35683412-DAB364E1-1DB8-4D25-96CE-39664FC553D7Q35758704-E74FD5CE-9CF0-4800-A573-9B8AAB5BDA27Q36028888-FC8BEDC7-3B41-4872-9F06-59F5375E76DFQ36109555-1C81C8A9-AF06-40D8-A1F8-1CE822D64CC9Q36142491-E96862D5-D040-42F7-A50E-ED96891722DFQ36400216-14EFFCAA-CFC3-4F7C-8317-C5F15015FBE5Q37545124-FEF08B53-1D78-4BCF-AB90-58D92B8CF70CQ37706099-D4E4E529-2FC7-4EFD-9AF6-6CA6DD437272Q38487996-C6D6A6F6-F34D-436B-A5B0-078E4B84CE93Q38509236-C64D8A93-011E-42A9-A894-4DAA864225B6Q38787315-D3A4BDD3-0FBA-4B21-A480-26B113883965Q38819678-B5712FAA-2EA6-4E70-9CF1-62015D7648D9Q38990822-A173FDD4-DF23-481B-B37C-960B6D4F855CQ41311492-83C99D31-49E4-4C08-95B7-0D30E116EF63Q41488763-DD2CE7D5-36EE-4316-A578-0C976F350418Q47100701-D13EBF9B-1555-46D8-BBA1-BE5476C09B1CQ47141024-D51ED1BB-865E-43AA-893B-3FE6A2F39814Q50240602-E06F2827-02CA-4829-BA8B-24424D9CAB8EQ51525251-2994ABF9-7892-4A9B-9498-9150DC7256DFQ51611913-359EA6C4-638B-40E4-9E1A-DD0012208F5DQ53209584-7B31B381-F356-43DC-8BCA-73163060211DQ55447528-B5F5DBEA-4C7B-47E9-AD6E-F179F3E7D9F3Q55709216-7EC03B66-7D1E-44AB-887E-3AEEF54AC883
P2860
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Six versus fewer planned cycle ...... is of individual patient data.
@ast
Six versus fewer planned cycle ...... is of individual patient data.
@en
type
label
Six versus fewer planned cycle ...... is of individual patient data.
@ast
Six versus fewer planned cycle ...... is of individual patient data.
@en
prefLabel
Six versus fewer planned cycle ...... is of individual patient data.
@ast
Six versus fewer planned cycle ...... is of individual patient data.
@en
P2093
P31
P50
P1433
P1476
Six versus fewer planned cycle ...... is of individual patient data.
@en
P2093
Barbara Parente
Bengt Bergman
Cesare Gridelli
Ciro Gallo
Fernando Barata
Francesco Perrone
Jong-Mu Sun
Keunchil Park
Mary E R O'Brien
P304
P356
10.1016/S1470-2045(14)70402-4
P577
2014-09-14T00:00:00Z